There are currently three FDA-approved biomarkers for determining eligibility for ICI treatment: tumor mutational burden (TMB), PD-L1 expression, and high microsatellite instability (MSI-H) and mismatch repair deficient (dMMR) status31. This evidence concerns the gene CD274 and neoplasm.